Remove 2015 Remove Labelling Remove Packaging
article thumbnail

Common pharma compliance concerns cited by FDA warning letters

European Pharmaceutical Review

However, the researchers noted that a larger number of warning letters were issued to pharmaceutical manufacturers (ie, by CDER) than to medical device manufacturers (by CDRH) between 2015 and 2020. The major reasons for this were poor cGMP compliance and misbranding.

article thumbnail

September 2023 Newsletter

Safe Biologics

6 would prevent the HHS Secretary from requiring a switching study as part of the data package to receive the interchangeable designation. This is the first biosimilar approved to treat systemic juvenile idiopathic arthritis, and the 43rd biosimilar approved by the FDA since 2015. However, S.6 ASBM surveys of U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Issues Long-Awaited QMSR Final Rule

FDA Law Blog: Biosimilars

This amendment marks the first significant revision of Part 820 since 1996, which established the Quality System (QS) regulation and “included requirements related to the methods used in, and the facilities and controls used for, designing, manufacturing, packaging, labeling, storing, installing, and servicing of devices intended for human use.”

article thumbnail

Drugs and Lactation

RX Note

In the past, package inserts were not always reliable sources of information regarding medication safety during lactation. As a general rule, breastfeeding is considered acceptable when the relative infant dose is <10%.

article thumbnail

Medication Safety

RX Note

Such events may be related to professional practice and healthcare products, procedures and systems, including prescribing; order communication; product labelling, packaging and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use.

article thumbnail

Pharmacologic Management of Crotalid Envenomation

Pharmacy Friday Pearls

Crofab ® [package insert]. Anavip ® [package insert]. in the treatment group vs 7.4 in the control group (95% CI 0.1 – 2.3; in the treatment group vs 7.4 in the control group (95% CI 0.1 – 2.3; Available at: [link] Accessed April 28, 2020. West Conshohocken, PA: BTG International Inc; 2000. Crotalidae Immune F(ab’)2 (Equine).

article thumbnail

Navigating the unique CMC challenges of oral anaerobic live biotherapeutics

European Pharmaceutical Review

Flexibility in packaging and label design may also be necessary, particularly where the physical dose size may require to be modified due to potency variations or multiple units may requiring dosing to achieve the target dose. 2015; 69(1):381–403 5. Leveraging Quorum Sensing to Manipulate Microbial Dynamics. 2021; 19:100306 4.

Dosage 97